SurgiQuest AirSeal in Robotic Partial Nephrectomy - (TARPAN Study)



Status:Completed
Conditions:Hospital
Therapuetic Areas:Other
Healthy:No
Age Range:18 - 80
Updated:4/2/2016
Start Date:October 2014
End Date:December 2015
Contact:cynthia Harris, BS
Email:cindy@clinregconsult.com
Phone:775-392-2970

Use our guide to learn which trials are right for you!

A Physician Preference Study of the Use of SurgiQuest AirSeal vs. Conventional Insufflation Systems for the Management of Pneumoperitoneum in Robotic Partial Nephrectomy .

A MULTI-CENTER, PROSPECTIVE, RANDOMIZED, CONTROLLED STUDY TO EVALUATE PHYSICIAN PREFERENCE
RELATED TO THE USE OF THE SURGIQUEST AIRSEAL INSUFFLATION SYSTEM (AIS) VS. CONVENTIONAL
INSUFFLATION SYSTEMS (CIS) FOR THE MANAGEMENT OF PNEUMOPERITONEUM DURING ROBOTIC PARTIAL
NEPHRECTOMY

A prospective, randomized, controlled multi-center clinical Study designed to evaluate
Physician Preference related to the use of the SurgiQuest AirSealTM Insufflation System
(AIS) vs. Conventional Insufflation Systems (CIS) for the Management of pneumoperitoneum
during Robotic Partial Nephrectomy. Subjects will be randomized in a 1:1:1 treatment device
to control ratio into one of three (3) different study arms: 1) AIS @ 12mmHg pressure, 2)
AIS @ 15mmHg pressure, and 3) CIS @ 15mmHg pressure. 189 randomized subjects distributed in
three arms of 63 patients. The three study sites are targeted to enroll 63 patients each, 21
patients in each of the three (3) study arms. It is expected that this will take up to 6
months.

Inclusion Criteria:

1. 18 to 80 years of age;

2. Capable and willing to give informed consent;

3. Acceptable candidate for an elective, non-emergent robotic partial nephrectomy;

Exclusion Criteria:

Subjects will be excluded from participating in this Study if they meet any of the
following criteria prior to initiation of the endoscopic procedure 1.Advanced refusal of
blood transfusion, if necessary; 2.Active systemic or cutaneous infection or inflammation;
3 Pre-existing immunodeficiency disorder and/or chronic use of systemic steroids;
4.Uncontrolled diabetes mellitus 5.Known, significant history of bleeding diathesis,
coagulopathy, von Willebrand's disease or current platelet count < 100,000 cells/mm3,
baseline INR ≥1.8, or fibrinogen level less than 150 mg/dl (if received a fibrinolytic
agent within prior 24 hours); 6.Severe co-existing morbidities having a life expectancy of
less than 30 days; 7.Currently involved in any other investigational clinical Studies;
8.Significant anemia with a hemoglobin level less than 10 g/dL or a hematocrit less than
30%; 9.Females who are pregnant, planning to become pregnant within 3 months of the
procedure, or lactating; 10.Extreme morbid obesity (BMI greater than 45 kg/m2) or
underweight (BMI less than 20 kg/m2); 11. Patients presenting with Ascites
We found this trial at
3
sites
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
New York, New York 10016
?
mi
from
New York, NY
Click here to add this to my saved trials
5300 Tallman Ave NW
Seattle, Washington 98122
(206) 782-2700
Swedish Medical Center Since 1910, Swedish has been the region's hallmark for excellence in health...
?
mi
from
Seattle, WA
Click here to add this to my saved trials